News Recent - Tellus BioVentures

News

Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease

08/15/22 Viridian Therapeutics, Inc. (NASDAQ: VRDN) today announced positive initial clinical data from the 10mg/kg cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED).

News

Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease

Recent Stories

Penn Spinout Vittoria Biotherapeutics Emerges from Stealth Mode with $10M Seed Round

Dianthus Therapeutics Launches with $100M to Develop Selective Antibody Complement Therapeutics to Treat Severe and Rare Autoimmune Diseases

Interius BioTherapeutics Announces Granting of US Patent to Support in Vivo Cell-Specific Gene Delivery Platform

Navrogen Closes $3.0M Seed Financing To Advance Its Preclinical Pipeline Targeting Humoral Immunosuppressed Cancers And Immune-Related Disorders

Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform

Two M&A deals and $9B later, Lonnie Moulder is ramping up his latest biotech startup. And this one comes with global vision built in.

MiRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments

MiRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.

FDA Grants Fast Track Status to Aegle Therapeutics’ AGLE-102 for the Treatment of Dystrophic Epidermolysis Bullosa

Aegle Therapeutics Completes $6.5M Series A Financing

Latest Penn biotech spinout taking on cancer raises $1.6M from investors

Zai Lab Appoints Lonnie Moulder to Board of Directors

Helsinn appoints Eric Cornut and Lonnie Moulder to the Board of Directors

Aegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis Bullosa